Integra LifeSciences (IART) to Release Earnings on Thursday

Integra LifeSciences (NASDAQ:IART) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Thursday, July 31st. Analysts expect Integra LifeSciences to post earnings of $0.43 per share and revenue of $395.06 million for the quarter. Integra LifeSciences has set its Q2 2025 guidance at 0.400-0.450 EPS and its FY 2025 guidance at 2.190-2.290 EPS.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Monday, May 5th. The life sciences company reported $0.41 earnings per share for the quarter, missing the consensus estimate of $0.43 by ($0.02). Integra LifeSciences had a negative net margin of 1.78% and a positive return on equity of 12.12%. The company had revenue of $382.65 million for the quarter, compared to analysts’ expectations of $381.17 million. During the same period in the previous year, the firm earned $0.55 earnings per share. The firm’s revenue for the quarter was up 3.7% on a year-over-year basis. On average, analysts expect Integra LifeSciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Integra LifeSciences Stock Down 1.8%

IART opened at $12.86 on Wednesday. The company has a quick ratio of 0.72, a current ratio of 1.21 and a debt-to-equity ratio of 0.81. The firm has a 50 day moving average price of $12.59 and a 200-day moving average price of $17.83. Integra LifeSciences has a twelve month low of $11.06 and a twelve month high of $27.13. The stock has a market capitalization of $999.35 million, a price-to-earnings ratio of -33.84, a PEG ratio of 0.73 and a beta of 1.15.

Hedge Funds Weigh In On Integra LifeSciences

Hedge funds have recently modified their holdings of the company. Dynamic Technology Lab Private Ltd bought a new position in shares of Integra LifeSciences in the first quarter worth approximately $277,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Integra LifeSciences by 5.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company’s stock worth $889,000 after purchasing an additional 1,975 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Integra LifeSciences by 23.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 244,335 shares of the life sciences company’s stock worth $5,373,000 after purchasing an additional 45,693 shares during the period. Finally, Goldman Sachs Group Inc. boosted its position in shares of Integra LifeSciences by 2.2% during the first quarter. Goldman Sachs Group Inc. now owns 1,660,511 shares of the life sciences company’s stock worth $36,515,000 after acquiring an additional 35,790 shares during the last quarter. 84.78% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. JMP Securities decreased their price objective on shares of Integra LifeSciences from $35.00 to $25.00 and set a “market outperform” rating for the company in a report on Friday, May 9th. JPMorgan Chase & Co. cut their target price on shares of Integra LifeSciences from $24.00 to $12.00 and set an “underweight” rating for the company in a research report on Tuesday, May 6th. Wells Fargo & Company cut their target price on shares of Integra LifeSciences from $25.00 to $13.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 6th. Finally, Truist Financial cut their target price on shares of Integra LifeSciences from $26.00 to $19.00 and set a “hold” rating for the company in a research report on Friday, April 11th. Four research analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $18.63.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.